Q2 Solutions will run Adaptive's NGS-based immune cell receptor profiling assay for its pharma and biotech clients, potentially in COVID-19 vaccine trials.
IQvia, the lead investor in this round, will work with BC Platforms to integrate genomic and clinical data in a secure environment to support biomedical research.
Now a subsidiary of IQvia, NLP vendor Linguamatics also is looking to help precision medicine providers and pharma researchers with phenotype-genotype matching.
The new IQvia E360 Genomics build includes a "privacy-preserving" database system and will soon have analytic tools to support genotype-phenotype research.
CRO and analytics giant IQvia, the product of the IMS Health-Quintiles merger, quietly purchased UK-based bioinformatics company Linguamatics a month ago.
The analytics firm formerly known as Quintiles IMS will offer researchers secure access to Genomics England's de-identified databases in pursuit of precision medicine.
The joint venture – of which Quintiles will own 60 percent and Quest will own 40 percent – is poised to be the second largest central laboratory services firm in the world.
The New York Times reports that experts say President Joe Biden's goal of vaccinating 1 million people a day in the US in the next 100 days is too low a bar.
